Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis in Japan

This article was originally published in The Tan Sheet

Executive Summary

Consumer Health division forms joint venture with household products company Kao to introduce OTC brands in Japan. The Novartis Kao portfolio will include new products developed for the Japanese market, international brands suitable for Japan and pharmaceuticals appropriate for switching from Rx status. In January 2001, the Tokyo-based firm will launch an eyecare product for the relief of eyestrain symptoms. Other products will target fatigue, muscle aches and back pain. McNeil Consumer Healthcare recently announced a partnership with Takeda Chemical Industries to launch Tylenol analgesics in Japan (1"The Tan Sheet" July 24, p. 19)

You may also be interested in...



Novartis Kao

Joint venture created by Novartis Consumer Health, Kao Corp. to market OTCs in Japan dissolved, firms announce March 26. Partnership was created in July 2000 with a portfolio expected to include new products developed for Japanese market, international brands, Rx drugs suitable for OTC switch (1"The Tan Sheet" Aug. 7, 2000, In Brief). Parent companies realized "initial expectations were not likely to be met within the timeframe they had originally agreed upon," Novartis says, adding it remains interested in increasing its OTC presence in Japan, particularly through switches...

Novartis Kao

Joint venture created by Novartis Consumer Health, Kao Corp. to market OTCs in Japan dissolved, firms announce March 26. Partnership was created in July 2000 with a portfolio expected to include new products developed for Japanese market, international brands, Rx drugs suitable for OTC switch (1"The Tan Sheet" Aug. 7, 2000, In Brief). Parent companies realized "initial expectations were not likely to be met within the timeframe they had originally agreed upon," Novartis says, adding it remains interested in increasing its OTC presence in Japan, particularly through switches...

Novartis Kao

Joint venture created by Novartis Consumer Health, Kao Corp. to market OTCs in Japan dissolved, firms announce March 26. Partnership was created in July 2000 with a portfolio expected to include new products developed for Japanese market, international brands, Rx drugs suitable for OTC switch (1"The Tan Sheet" Aug. 7, 2000, In Brief). Parent companies realized "initial expectations were not likely to be met within the timeframe they had originally agreed upon," Novartis says, adding it remains interested in increasing its OTC presence in Japan, particularly through switches...

Related Content

Topics

UsernamePublicRestriction

Register

PS091513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel